title: Inhibition of xanthine oxidase by 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine.
abstract: Compound B103U, 4-hydroxy-6-mercaptopyrazolo[3,4-d]pyrimidine, was investigated as an inhibitor of human xanthine oxidase. Studies in vitro demonstrated that it was significantly more potent than oxypurinol, 4,6-dihydroxypyrazolo[3,4-d]pyrimidine. It formed an initial complex with electron-rich (reduced) human xanthine oxidase that was tighter than the corresponding complex formed by oxypurinol. The initial complexes with each inhibitor and reduced enzyme were internally rearranged into more stable complexes with first-order rate constants of 2.5 to 3 per min. However, the half-life of the isomerized (stable) complex with B103U was three to four times longer than the half-life of the analogous complex with oxypurinol. This stability was previously noted by Massey et al. (J. Biol Chem 254: 2837-2844, 1970) with B103U and bovine xanthine oxidase. The overall Ki values accounting for the initial and isomerized complexes were 5 nM for B103U and 100 nM for oxypurinol. B103U was also more potent as an inhibitor of bovine xanthine oxidase-catalyzed generation of superoxide radicals. Studies in mice revealed that the relative in vitro potency of B103U was not sustained in vivo. Compared to the inhibition of xanthine oxidase by oxypurinol, inhibition by B103U was neither more potent nor longer lasting. This shortcoming was not caused by weaker inhibition of mouse xanthine oxidase. Instead, it was the result of poor bioavailability. Plasma levels of available B103U rapidly decreased from samples of mouse and human blood because of reversible binding to serum proteins. B103U was also susceptible to oxidation. Two equivalents of H2O2 stoichiometrically oxidized the 6-thiol substituent to a sulfinic acid. This oxidized product was three orders of magnitude weaker as an inhibitor of xanthine oxidase than was B103U.
authors.affiliation: Wellcome Research Laboratory, Research Triangle Park, NC 27709.
authors.forename: T
authors.initials: T
authors.lastname: Spector
authors.forename: W W
authors.initials: WW
authors.lastname: Hall
authors.forename: D J
authors.initials: DJ
authors.lastname: Porter
authors.forename: C U
authors.initials: CU
authors.lastname: Lambe
authors.forename: D J
authors.initials: DJ
authors.lastname: Nelson
authors.forename: T A
authors.initials: TA
authors.lastname: Krenitsky
mesh_terms: D000818:Animals; D001798:Blood Proteins / Q000378:metabolism; D002851:Chromatography, High Pressure Liquid; D005609:Free Radicals; D006801:Humans; D006861:Hydrogen Peroxide; D019271:Hypoxanthine; D007042:Hypoxanthines; D007700:Kinetics; D051379:Mice; D010117:Oxypurinol / Q000031:analogs & derivatives / Q000493:pharmacokinetics / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D013481:Superoxides / Q000378:metabolism; D014527:Uric Acid / Q000378:metabolism; D014969:Xanthine Oxidase / Q000037:antagonists & inhibitors*
chemical_list: D001798:Blood Proteins; D005609:Free Radicals; D007042:Hypoxanthines; D011743:Pyrimidines; D013481:Superoxides; D014527:Uric Acid; D019271:Hypoxanthine; C021269:oxithiopurinol; D006861:Hydrogen Peroxide; D014969:Xanthine Oxidase; D010117:Oxypurinol